nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.03.2011 | Original Paper

Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer

verfasst von: Mary A. Bewick, Robert M. Lafrenie, Michael S. C. Conlon

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Inter-individual variations in treatment efficacy may be influenced by polymorphisms in DNA repair genes. We investigated the association of 3 functional polymorphisms in the nucleotide excision repair (NER) pathway with survival outcome of 95 patients with metastatic breast cancer (MBC) treated with DNA-damaging chemotherapy.

Methods

ERCC1 8092 C/A, ERCC2 Asp312Asn and ERCC2 Lys751Gln were determined using Taqman-based genotyping assays. Genotype associations with breast cancer-specific survival (BCSS) and progression-free survival (PFS) were evaluated using Kaplan–Meier estimates and hazard ratios calculated using Cox regression analysis. Tests for trend were conducted by calculating P-values for the HR coefficient in proportional hazards regression models.

Results

ERCC2 Lys751Gln was significantly associated with BCSS (median: 24.8 months for AA/AC combined and 14.2 months for CC, HR: 1.9 (95% CI 1.06–3.26)). Median BCSS decreased with increasing number of designated adverse genotypes for the 3 polymorphisms (P_trend = 0.003). Risk estimates for PFS were nonsignificantly elevated and were significantly elevated for BCSS for patients with 2 (HR = 2.21, 95% CI: 1.04–4.72) or 3 (HR = 6.67, 95% CI: 2.19–20.29) adverse genotypes. In treatment subgroup analysis, risk estimates for BCSS were significantly elevated for patients with 3 adverse genotypes treated with cyclophosphamide, mitoxantrone and vinblastine (HR: 11.9, 95% CI 1.77–79.51) and P_trend = 0.02 for increasing number of adverse genotypes. Risk of progression was significantly increased for patients with 1 adverse genotype treated with cyclophosphamide, mitoxantrone and carboplatin (HR: 3.5, 95% CI 1.19–10.6) and P_trend = 0.02 for increasing number of adverse genotypes.

Conclusion

Polymorphisms in NER pathway may impact survival outcome for patients with MBC following treatment with DNA-damaging chemotherapy. These results provide support for a polygenic pathway approach for assessing the prognostic and predictive potential of polymorphisms in treatment outcome.

Abdel-Rahman SZ, El-Zein RA (2000) The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett 159:63–71CrossRefPubMed

Affatato AA, Wolfe KJ, Lopez MS et al (2004) Effect of XPD/ERCC2 polymorphisms on chromosome aberration frequencies in smokers and on sensitivity to the mutagenic tobacco-specific nitrosamine NNK. Environ Mol Mutagen 44:65–73CrossRefPubMed

Altaha R, Liang X, Yu JJ et al (2004) Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14:959–970PubMed

Ambrosone CB, Ahn J, Singh KK et al (2005) Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res 65:1105–1111PubMed

Ambrosone CB, Tian C, Ahn J et al (2006) Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a case-series study. Breast Cancer Res 8:R40CrossRefPubMed

Andersson BS, Sadeghi T, Siciliano MJ et al (1996) Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother Pharmacol 38:406–416CrossRefPubMed

Au WW, Salama SA, Sierra-Torres CH (2003) Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 111:1843–1850CrossRefPubMed

Au WW, Navasumrit P, Ruchirawat M (2004) Use of biomarkers to characterize functions of polymorphic DNA repair genotypes. Int J Hyg Environ Health 207:301–313CrossRefPubMed

Azuma K, Komohara Y, Sasada T et al (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98:1336–1343CrossRefPubMed

Benhamou S, Sarasin A (2005) ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol 161:1–14CrossRefPubMed

Bewick MA, Conlon MS, Lafrenie RM (2006) Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol 24:5645–5651CrossRefPubMed

Bewick MA, Conlon MS, Lafrenie RM (2008) Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer. Breast Cancer Res Treat 111:93–101CrossRefPubMed

Booton R, Ward T, Heighway J et al (2006) Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer 106:2421–2427CrossRefPubMed

Bradbury PA, Kulke MH, Heist RS et al (2009) Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics 19:613–625CrossRefPubMed

Carles J, Monzo M, Amat M et al (2006) Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys 66:1022–1030CrossRefPubMed

Caronia D, Patino-Garcia A, Milne RL et al (2009) Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 9:347–353CrossRefPubMed

Chen P, Wiencke J, Aldape K et al (2000) Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 9:843–847PubMed

Chew HK, Doroshow JH, Frankel P et al (2009) Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 27:2163–2169CrossRefPubMed

Duell EJ, Wiencke JK, Cheng TJ et al (2000) Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21:965–971CrossRefPubMed

Durr FE, Wallace RE & Citarella RV (1983) Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev 10 Suppl B:3-11

Farquhar CM, Marjoribanks J, Lethaby A et al (2007) High dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis. Cancer Treat Rev 33:325–337CrossRefPubMed

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1–22CrossRefPubMed

Gurubhagavatula S, Liu G, Park S et al (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594–2601CrossRefPubMed

Handra-Luca A, Hernandez J, Mountzios G et al (2007) Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 13:3855–3859CrossRefPubMed

Herrera M, Dominguez G, Garcia JM et al (2009) Differences in repair of DNA cross-links between lymphocytes and epithelial tumor cells from colon cancer patients measured in vitro with the comet assay. Clin Cancer Res 15:5466–5472CrossRefPubMed

Hou SM, Falt S, Angelini S et al (2002) The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis 23:599–603CrossRefPubMed

Hutsell SQ, Sancar A (2005) Nucleotide excision repair, oxidative damage, DNA sequence polymorphisms, and cancer treatment. Clin Cancer Res 11:1355–1357CrossRefPubMed

Kamikozuru H, Kuramochi H, Hayashi K et al (2008) ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. Int J Oncol 32:1091–1096PubMed

Le Morvan V, Bellott R, Moisan F et al (2006) Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-a-vis the NCI-60 panel. Pharmacogenomics 7:843–852CrossRefPubMed

Le Morvan V, Smith D, Laurand A et al (2007) Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 8:1693–1703CrossRefPubMed

Lee HW, Han JH, Kim JH et al. (2007) Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer

Lin J, Swan GE, Shields PG et al (2007) Mutagen sensitivity and genetic variants in nucleotide excision repair pathway: genotype-phenotype correlation. Cancer Epidemiol Biomarkers Prev 16:2065–2071CrossRefPubMed

Lunn RM, Helzlsouer KJ, Parshad R et al (2000) XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21:551–555CrossRefPubMed

Matullo G, Palli D, Peluso M et al (2001) XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22:1437–1445CrossRefPubMed

McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180–1184CrossRefPubMed

Nagle CM, Chenevix-Trench G, Spurdle AB et al (2007) The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer 43:283–290CrossRefPubMed

Nowell SA, Ahn J, Rae JM et al (2005) Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91:249–258CrossRefPubMed

Petty WJ, Knight SN, Mosley L et al (2007) A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer. J Thorac Oncol 2:197–202CrossRefPubMed

Quintela-Fandino M, Hitt R, Medina PP et al (2006) DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 24:4333–4339CrossRefPubMed

Reed E (2005) ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 11:6100–6102CrossRefPubMed

Reed E, Kohn EC, Sarosy G et al (1995) Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol 22:90–96PubMed

Rzeszowska-Wolny J, Polanska J, Pietrowska M et al (2005) Influence of polymorphisms in DNA repair genes XPD, XRCC1 and MGMT on DNA damage induced by gamma radiation and its repair in lymphocytes in vitro. Radiat Res 164:132–140CrossRefPubMed

Simon GR, Ismail-Khan R, Bepler G (2007) Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol 39:1318–1328CrossRefPubMed

Spitz MR, Wu X, Wang Y et al (2001) Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61:1354–1357PubMed

Suk R, Gurubhagavatula S, Park S et al (2005) Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 11:1534–1538CrossRefPubMed

Vodicka P, Kumar R, Stetina R et al (2004) Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis 25:757–763CrossRefPubMed

Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307–320CrossRefPubMed

Wolfe KJ, Wickliffe JK, Hill CE et al (2007) Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet Genomics 17:897–905CrossRefPubMed

Wu X, Gu J, Wu TT et al (2006) Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24:3789–3798CrossRefPubMed

Wu X, Lu C, Ye Y et al (2008) Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 18:955–965CrossRefPubMed

Zhang CC, Yang JM, Bash-Babula J et al (1999) DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. Cancer Res 59:3663–3670PubMed

Zhang Y, Rohde LH, Wu H (2009) Involvement of nucleotide excision and mismatch repair mechanisms in double strand break repair. Curr Genomics 10:250–258CrossRefPubMed

Zhou W, Gurubhagavatula S, Liu G et al (2004) Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10:4939–4943CrossRefPubMed

Titel: Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer
verfasst von: Mary A. Bewick
Robert M. Lafrenie
Michael S. C. Conlon
Publikationsdatum: 01.03.2011
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2011
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-010-0915-7

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

L-methionine-induced alterations in molecular signatures in MCF-7 and LNCaP cancer cells

Impact of age on morbidity and outcome of concurrent radiochemotherapy in high-risk FIGO stage I to IVA carcinoma of the uterine cervix following laparoscopic surgery

Overexpression of T lymphoma invasion and metastasis 1 predict renal cell carcinoma metastasis and overall patient survival

Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma

Differential induction of reactive oxygen species through Erk1/2 and Nox-1 by FK228 for selective apoptosis of oncogenic H-Ras-expressing human urinary bladder cancer J82 cells

Neural cell adhesion molecule isoform 140 declines with rise of WHO grade in human gliomas and serves as indicator for the invasion zone of multiform glioblastomas and brain metastases

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie